Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.
The letter came in June. Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. What? she remembers thinking.
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug.
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Pedersen and Mariam Sunny LONDON/COPENHAGEN (Reuters) -Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.
Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results from a new drug study caused investors to flee the drugmaker. The Danish producer of Ozempic,
Novo Nordisk's drug trial results weaken Danish currency
The Danish crown weakened on Friday, after disappointing results from a late-stage trial of a new weight-loss drug drove a big fall in the shares of Denmark's largest company, Novo Nordisk.
Hosted on MSN2d
What to Know About Ozempic, Wegovy and the New Weight-Loss Market
Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...
Foods to avoid if you are taking Ozempic or Wegovy for weight loss
Skipping certain foods can help patients manage nausea and other side effects of the popular drugs, doctors say.
Is Zepbound or Wegovy Better for Weight Loss? One Can Help You Shed 50 Lbs
With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...
WHYY1d
Greater Philly’s largest health insurer to restrict coverage for weight loss medications, citing ‘exorbitant costs’
Independence Blue Cross joins other insurance companies in restricting coverage of Wegovy and Ozempic to Type 2 diabetes and ...
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
Half a million people buying weight-loss jabs online because of ‘slow’ NHS rollout
More than half a million people are buying weight-loss injections online because of the “slow” rollout of the drugs by the ...
Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
USA Today21d
Why your co-pay for weight loss drugs like Wegovy just went through the roof
For Debbie Halstead, the weight loss medication Wegovy has been nothing short of a miracle. The Cool Ridge, West Virginia, woman shed 60 pounds and lowered her blood pressure nearly 60 points.
The Globe and Mail26d
Wegovy vs. Ozempic: Which is the Better Choice for Weight Loss?
Wegovy is specifically licensed and approved for weight management in the UK, whereas Ozempic is primarily intended to treat diabetes but can be used off-label for weight loss . The dosage of ...